Bayer (ETR:BAYN) named strategy chief Werner Baumann to replace Marijn Dekkers as CEO today, prompting some industry watchers to speculate that there’s more deal-making ahead for the German firm’s non-pharma markets.
Baumann, who’s slated to succeed Dekkers May 1, joined Bayer in 1988 and made a name for himself with the successful integration of rival drugmaker Schering in 2006 – at the time Bayer’s biggest-ever takeover – and was a driving force behind the acquisition of Merck & Co’s consumer health unit 8 years later.
Investment bankers who know him describe Baumann as introverted and indifferent to executive trappings, but said this should not be confused with a lack of determination.
“Werner Baumann shouldn’t be underestimated. He won’t hesitate to do a deal if it fits,” one of them said.
Cornell dean is Dana-Farber’s 1st female CEO
The Dana-Farber Cancer Institute appointed Dr. Laurie Glimcher to be its 1st female CEO. Glimcher, an immunologist, is dean of Cornell University’s medical college, Weill Cornell Medicine. She’s slated to replace Dr. Edward Benz in January 2017.
Calmare Therapeutics names Chansky as regulatory chief
Calmare Therapeutics said it named Dr. Christine Chansky to be its new chief regulatory officer.
- Intersect ENT names Thoratec’s Lehman as general counsel
- Battelle names Geppert as senior research leader
- DiaMedica names Verdoorn as neuroscience veep
- Apollo Medical taps Burns for physician services SVP
- Ex-Thoratec CEO Grossman joins TherOx board
Material for Reuters was used in this report.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.